Several studies have described high rates of KLK7 positivity in triple negative breast cancer [17], colorectal cancer [21], ovarian cancer [12–14], adenocarcinomas of the cervix uteri [23, 24], pancreatic cancer [10, 11] and malignant melanoma [19], but the published data on the prevalence of KLK7 immunostaining are discrepant for several tumor entities. This evidence concerns the gene KLK7 and ovarian carcinoma.